Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2023-05-08 00:00:00 ET · period of report 2023-05-04 · accession 0001929354-23-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2023-05-08	2023-05-04+	AVTX	Caissa Capital Management ltd.	10%	P - Purchase	$2.77	+25.0K	1.34M	+2%	+$69.3K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-04	P	A	15,000	$2.79	1,332,700	I See Footnote (1)	—	—	(F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
2	Common	Common Stock	2023-05-08	P	A	5,000	$2.62	1,342,700	I See Footnote (1)	—	—	(F4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
3	Common	Common Stock	2023-05-05	P	A	5,000	$2.88	1,337,700	I See Footnote (1)	—	—	(F3) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.